Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI

被引:60
作者
Redfors, Bjorn [1 ,2 ,3 ]
Furer, Ariel [1 ,4 ,5 ]
Selker, Harry P. [6 ]
Thiele, Holger [7 ,8 ]
Patel, Manesh R. [9 ]
Chen, Shmuel [1 ,2 ]
Udelson, James E. [10 ]
Ohman, E. Magnus [9 ]
Eitel, Ingo [11 ,12 ]
Granger, Christopher B. [9 ]
Maehara, Akiko [1 ,2 ]
Kirtane, Ajay J. [1 ,2 ]
Genereux, Philippe [1 ,13 ,14 ]
Jenkins, Paul L. [15 ]
Ben-Yehuda, Ori [1 ,2 ]
Stone, Gregg W. [1 ,16 ]
机构
[1] Cardiovasc Res Fdn, Clin Trials Ctr, New York, NY USA
[2] Columbia Univ, Med Ctr, Dept Cardiol, NewYork Presbyterian Hosp, New York, NY USA
[3] Sahlgrens Univ Hosp, Dept Cardiol, Gothenburg, Sweden
[4] Israel Def Forces, Med Corps, Tel Hashomer, Israel
[5] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mil Med, Jerusalem, Israel
[6] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA
[7] Univ Leipzig, Heart Ctr Leipzig, Leipzig, Germany
[8] Leipzig Heart Inst, Leipzig, Germany
[9] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA
[10] Tufts Med Ctr, Div Cardiol, Boston, MA 02111 USA
[11] Univ Heart Ctr Lubeck, Univ Hosp Schleswig Holstein, Med Clin Cardiol Angiol Intens Care Med 2, Lubeck, Germany
[12] German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Kiel Lubeck, Lubeck, Germany
[13] Morristown Med Ctr, Gagnon Cardiovasc Inst, Morristown, NJ USA
[14] Hop Sacre Coeur Montreal, Montreal, PQ, Canada
[15] Mary Imogene Bassett Hosp, Cooperstown, NY USA
[16] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
infarct size; percutaneous coronary intervention (PCI); smoking; ST-segment elevation myocardial infarction (STEMI); ACUTE MYOCARDIAL-INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RECEIVING THROMBOLYTIC THERAPY; BOLUS ABCIXIMAB APPLICATION; SMOKERS PARADOX; CIGARETTE-SMOKING; POOLED ANALYSIS; GUSTO-I; SIZE; TRIAL;
D O I
10.1016/j.jacc.2020.02.045
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Smoking is a well-established risk factor for ST-segment elevation myocardial infarction (STEMI); however, once STEMI occurs, smoking has been associated with favorable short-term outcomes, an observation termed the "smoker's paradox." It has been postulated that smoking might exert protective effects that could reduce infarct size, a strong independent predictor of worse outcomes after STEMI. OBJECTIVES The purpose of this study was to determine the relationship among smoking, infarct size, microvascular obstruction (MVO), and adverse outcomes after STEMI. METHODS Individual patient-data were pooled from 10 randomized trials of patients with STEMI undergoing primary percutaneous coronary intervention. Infarct size was assessed at median 4 days by either cardiac magnetic resonance imaging or technetium-99m sestamibi single-photon emission computed tomography. Multivariable analysis was used to assess the relationship between smoking, infarct size, and the 1-year rates of death or heart failure (HF) hospitalization and reinfarction. RESULTS Among 2,564 patients with STEMI, 1,093 (42.6%) were recent smokers. Smokers were 10 years younger and had fewer comorbidities. Infarct size was similar in smokers and nonsmokers (adjusted difference: 0.0%; 95% confidence interval [CI]: -3.3% to 3.3%; p = 0.99). Nor was the extent of MVO different between smokers and nonsmokers. Smokers had lower crude 1-year rates of all-cause death (1.0% vs. 2.9%; p < 0.001) and death or HF hospitalization (3.3% vs. 5.1%; p = 0.009) with similar rates of reinfarction. After adjustment for age and other risk factors, smokers had a similar 1-year risk of death (adjusted hazard ratio [adjHR]: 0.92; 95% CI: 0.46 to 1.84) and higher risks of death or HF hospitalization (adjHR: 1.49; 95% CI: 1.09 to 2.02) as well as reinfarction (adjHR: 1.97; 95% CI: 1.17 to 3.33). CONCLUSIONS In the present large-scale individual patient-data pooled analysis, recent smoking was unrelated to infarct size or MVO, but was associated with a worse prognosis after primary PCI in STEMI. The smoker's paradox may be explained by the younger age and fewer cardiovascular risk factors in smokers compared with nonsmokers. (C) 2020 by the American College of Cardiology Foundation.
引用
收藏
页码:1743 / 1754
页数:12
相关论文
共 45 条
  • [1] Paradoxical Association of Smoking With In-Hospital Mortality Among Patients Admitted With Acute Ischemic Stroke
    Ali, Syed F.
    Smith, Eric E.
    Bhatt, Deepak L.
    Fonarow, Gregg C.
    Schwamm, Lee H.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2013, 2 (03):
  • [2] The pathophysiology of cigarette C-V smoking and cardiovascular disease - An update
    Ambrose, JA
    Barua, RS
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (10) : 1731 - 1737
  • [3] The smoker's paradox: Insights from the angiographic substudies of the TIMI trials
    Angeja, BG
    Kermgard, S
    Chen, MS
    McKay, M
    Murphy, SA
    Antman, EM
    Cannon, CP
    Braunwald, E
    Gibson, CM
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2002, 13 (03) : 133 - 139
  • [4] ISOLATION AND SEQUENCE DETERMINATION OF RAT ISLET AMYLOID POLYPEPTIDE
    ASAI, J
    NAKAZATO, M
    KANGAWA, K
    MATSUKURA, S
    MATSUO, H
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 164 (01) : 400 - 405
  • [5] The "smoker's paradox" in patients with acute coronary syndrome: a systematic review
    Aune, Erlend
    Roislien, Jo
    Mathisen, Mariann
    Thelle, Dag S.
    Otterstad, Jan Erik
    [J]. BMC MEDICINE, 2011, 9
  • [6] EVALUATION OF PARADOXIC BENEFICIAL-EFFECTS OF SMOKING IN PATIENTS RECEIVING THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION - MECHANISM OF THE SMOKERS PARADOX FROM THE GUSTO-I TRIAL, WITH ANGIOGRAPHIC INSIGHTS
    BARBASH, GI
    REINER, J
    WHITE, HD
    WILCOX, RG
    ARMSTRONG, PW
    SADOWSKI, Z
    MORRIS, D
    AYLWARD, P
    WOODLIEF, LH
    TOPOL, EJ
    CALIFF, RM
    ROSS, AM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (05) : 1222 - 1229
  • [7] SIGNIFICANCE OF SMOKING IN PATIENTS RECEIVING THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION - EXPERIENCE GLEANED FROM THE INTERNATIONAL TISSUE PLASMINOGEN-ACTIVATOR STREPTOKINASE MORTALITY TRIAL
    BARBASH, GI
    WHITE, HD
    MODAN, M
    DIAZ, R
    HAMPTON, JR
    HEIKKILA, J
    KRISTINSSON, A
    MOULOPOULOS, S
    ERNESTO
    PAOLASSO
    VANDERWERF, T
    PEHRSSON, K
    SANDOE, E
    SIMES, J
    WILCOX, RG
    VERSTRAETE, M
    VONDERLIPPE, G
    VANDEWERF, F
    [J]. CIRCULATION, 1993, 87 (01) : 53 - 58
  • [8] Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials
    de Waha, Suzanne
    Patel, Manesh R.
    Granger, Christopher B.
    Ohman, E. Magnus
    Maehara, Akiko
    Eitel, Ingo
    Ben-Yehuda, Ori
    Jenkins, Paul
    Thiele, Holger
    Stone, Gregg W.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 (47) : 3502 - +
  • [9] Bupropion for Smoking Cessation in Patients Hospitalized With Acute Myocardial Infarction A Randomized, Placebo-Controlled Trial
    Eisenberg, Mark J.
    Grandi, Sonia M.
    Gervais, Andre
    O'Loughlin, Jennifer
    Paradis, Gilles
    Rinfret, Stephane
    Sarrafzadegan, Nizal
    Sharma, Sat
    Lauzon, Claude
    Yadav, Rakesh
    Pilote, Louise
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (05) : 524 - 532
  • [10] Intracoronary Compared With Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction
    Eitel, Ingo
    Woehrle, Jochen
    Suenkel, Henning
    Meissner, Josephine
    Kerber, Sebastian
    Lauer, Bernward
    Pauschinger, Matthias
    Birkemeyer, Ralf
    Axthelm, Christoph
    Zimmermann, Rainer
    Neuhaus, Petra
    Brosteanu, Oana
    de Waha, Suzanne
    Desch, Steffen
    Gutberlet, Matthias
    Schuler, Gerhard
    Thiele, Holger
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (13) : 1447 - 1454